Fortress Biotech, Inc. (FBIO) Operating Margin
- Operating margin · 12 months: Value -42.61%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -42.61% | Operating income / revenue. Period ending 2026-06-30. $-29.18M ÷ $68.47M × 100 ≈ -42.61% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -29.18M USD | Operating Income (Loss) |
| Revenue | 68.47M USD | |
| Cost of products and services | 23.56M USD | Cost of Goods and Services Sold |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | 68.67M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-29.18M | $68.47M | $23.56M | (m) | $68.67M | -42.61% |
| 2026-03-31 | $-55.64M | $66.16M | $22.35M | (m) | $86.63M | -84.10% |
| 2025-12-31 | $-70.22M | $63.26M | $20.92M | (m) | $96.40M | -111.00% |
| 2025-09-30 | $-89.27M | $62.30M | $20.16M | (m) | $108.53M | -143.28% |
| 2025-06-30 | $-104.82M | $59.30M | $18.88M | (m) | $113.38M | -176.75% |
| 2025-03-31 | $-96.13M | (m) | $19.67M | (m) | $95.45M | (m) |
| 2024-12-31 | $-110.38M | $57.67M | $20.88M | (m) | $87.73M | -191.38% |
| 2024-09-30 | $-106.16M | $62.50M | $24.66M | $61.02M | $83.48M | -169.85% |
| 2024-06-30 | $-97.72M | $82.62M | $25.80M | $71.92M | $83.12M | -118.27% |
| 2024-03-31 | $-120.04M | $85.11M | $27.03M | $91.40M | $86.72M | -141.04% |
| 2023-12-31 | $-142.34M | $84.51M | $26.66M | $106.07M | $94.12M | -168.43% |
| 2023-09-30 | $-177.36M | $80.97M | $28.36M | $127.12M | $99.71M | -219.04% |
| 2023-06-30 | $-214.34M | $62.75M | $29.16M | $136.67M | $108.12M | -341.59% |
| 2023-03-31 | $-215.16M | $64.25M | $29.02M | $137.66M | $112.73M | -334.90% |
| 2022-12-31 | $-203.56M | $75.74M | $30.77M | $134.88M | $113.66M | -268.76% |
| 2022-09-30 | $-210.93M | $77.61M | $32.58M | $142.81M | $113.16M | -271.77% |
| 2022-06-30 | $-213.86M | $82.17M | $36.53M | $144.73M | $105.24M | -260.26% |
| 2022-03-31 | $-205.79M | $81.13M | $36.38M | $145.43M | $95.57M | -253.66% |
| 2021-12-31 | $-188.54M | $68.79M | $32.08M | $128.87M | $86.84M | -274.08% |
| 2021-09-30 | $-150.84M | $64.26M | $26.84M | $103.77M | $74.95M | -234.72% |
| 2021-06-30 | $-120.22M | $52.65M | $19.05M | $85.71M | $68.11M | -228.32% |
| 2021-03-31 | $-102.76M | $44.27M | $14.69M | $69.15M | $63.19M | -232.13% |
| 2020-12-31 | $-94.27M | $45.60M | $14.59M | $64.11M | $61.17M | -206.74% |
| 2020-09-30 | $-100.35M | $42.98M | $13.87M | (m) | $59.69M | -233.48% |
| 2020-06-30 | $-99.84M | $43.28M | $13.20M | (m) | $58.64M | -230.71% |
| 2020-03-31 | $-99.74M | $43.07M | $12.46M | (m) | $57.63M | -231.57% |
| 2019-12-31 | $-110.82M | $36.63M | $10.53M | $81.33M | $55.59M | -302.54% |
| 2019-09-30 | $-112.66M | $34.49M | $8.55M | (m) | (m) | -326.65% |
| 2019-06-30 | $-118.33M | $29.89M | (m) | (m) | (m) | -395.85% |
| 2019-03-31 | $-118.43M | $27.46M | $6.54M | $81.65M | (m) | -431.36% |
| 2018-12-31 | $-120.00M | $26.88M | $6.13M | $83.33M | (m) | -446.38% |
| 2018-09-30 | $-112.81M | $228.27M | (m) | (m) | (m) | -49.42% |
| 2018-06-30 | $-120.52M | $211.46M | (m) | (m) | (m) | -56.99% |
| 2018-03-31 | $-119.12M | $198.33M | (m) | $44.09M | (m) | -60.06% |
| 2017-12-31 | $-101.21M | $187.58M | (m) | $52.49M | (m) | -53.95% |
| 2017-09-30 | $-92.61M | $154.88M | (m) | (m) | (m) | -59.79% |
| 2017-06-30 | $-76.25M | $108.97M | (m) | (m) | (m) | -69.98% |
| 2017-03-31 | $-68.20M | $60.50M | (m) | $-34.47M | (m) | -112.72% |
| 2016-12-31 | $-65.71M | $16.48M | (m) | $-35.13M | (m) | -398.73% |
| 2016-09-30 | $-59.10M | $4.20M | (m) | $26.65M | (m) | -1406.11% |
| 2016-06-30 | $-60.92M | $3.25M | (m) | $28.44M | (m) | -1872.89% |
| 2016-03-31 | $-53.55M | $1.02M | (m) | $24.50M | (m) | -5234.70% |
| 2015-12-31 | $-50.53M | $863.00K | (m) | $18.40M | (m) | -5855.27% |
| 2015-09-30 | $-42.87M | (m) | (m) | $14.94M | (m) | (m) |
| 2015-06-30 | $-29.14M | (m) | (m) | $7.44M | (m) | (m) |
| 2015-03-31 | $-26.14M | (m) | (m) | $7.39M | (m) | (m) |
| 2014-12-31 | $-20.65M | (m) | (m) | $10.24M | (m) | (m) |
| 2014-09-30 | $-25.21M | (m) | (m) | $15.03M | (m) | (m) |
| 2014-06-30 | $-28.37M | (m) | (m) | $18.78M | (m) | (m) |
| 2014-03-31 | $-33.90M | (m) | (m) | $24.20M | (m) | (m) |
| 2013-12-31 | $-35.78M | (m) | (m) | $25.68M | (m) | (m) |
| 2013-09-30 | $-34.55M | (m) | (m) | $23.70M | (m) | (m) |
| 2013-06-30 | $-32.88M | (m) | (m) | $22.12M | (m) | (m) |
| 2013-03-31 | $-29.05M | (m) | (m) | $18.86M | (m) | (m) |
| 2012-12-31 | $-27.18M | (m) | (m) | $17.47M | (m) | (m) |
| 2012-09-30 | $-24.11M | (m) | (m) | $16.34M | (m) | (m) |
| 2012-06-30 | $-21.81M | (m) | (m) | $14.31M | (m) | (m) |
| 2012-03-31 | $-19.08M | (m) | (m) | $11.92M | (m) | (m) |
| 2011-12-31 | $-35.04M | (m) | (m) | $8.58M | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-9.24M | (m) | (m) | $8.34M | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-2.61M | (m) | (m) | $2.27M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |